3,5-dipentadecyloxybenzonitrile | 198474-58-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3,5-dipentadecyloxybenzonitrile
• 英文别名: 3,5-di(pentadecoxy)benzonitrile
• CAS: 198474-58-7
• 化学式: C₃₇H₆₅NO₂
• 分子量: 555.929
• InChiKey: HUDBNMWMSVTGHD-UHFFFAOYSA-N

物化性质

• 沸点：
  628.6±45.0 °C(Predicted)
• 密度：
  0.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  16
• 重原子数：
  40
• 可旋转键数：
  30
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲醇 、 3,5-dipentadecyloxybenzonitrile 在 盐酸 作用下， 以 苯 为溶剂， 反应 1.0h， 以0.28 g的产率得到3,5-dipentadecyloxy-α-methoxy-α-iminotoluene hydrochloride
  参考文献：
  名称：

  COATING COMPOSITION AND MEDICAL DEVICE

  摘要：

  公开号：

  EP2954908B1
• 作为产物：
  描述：

  溴代十五烷 、 3,5-二羟基苯甲腈 在 potassium carbonate 作用下， 以 水 、 丙酮 为溶剂， 生成 3,5-dipentadecyloxybenzonitrile
  参考文献：
  名称：

  Amidine derivatives and drug carriers comprising the same

  摘要：

  公式（1）中的新型酰胺衍生物；以及包含这些衍生物的药物载体，如脂质体或乳化液，可以有效且安全地封闭遗传物质或药物并将其转移至细胞或受影响的部位。其中A是芳香环，R1和R2相同或不同且独立地代表具有10到25个碳原子中的任意一种的烷基基团或具有10到25个碳原子中的任意一种的烯基基团，X和Y相同或不同且独立地代表—O—、—S—、—COO—、—OCO—、—CONH—或—NHCO—，m为0或1，n为0或1到6之间的自然数。

  公开号：

  US06228391B1

文献信息

• Amidine derivatives and drug carriers comprising the same
  申请人：Terumo Kabushiki Kaisha

  公开号：US06228391B1

  公开（公告）日：2001-05-08

  Novel amidine derivatives of the formula (1); and drug carriers such as liposomes or emulsions comprising the derivatives, which can enclose genetic materials or drugs and transfer them to cells or affected sites efficiently and safely, wherein A is an aromatic ring, R1 and R2 are the same or different and independently represent an alkyl group having any one of 10 to 25 carbon atoms, and an alkenyl group having any one of 10 to 25 carbon atoms, X and Y are the same or different and independently represent —O—, —S—, —COO—, —OCO—, —CONH—, or —NHCO—, m is 0 or 1, and n is 0 or a natural number of 1 to 6.

  公式（1）中的新型酰胺衍生物；以及包含这些衍生物的药物载体，如脂质体或乳化液，可以有效且安全地封闭遗传物质或药物并将其转移至细胞或受影响的部位。其中A是芳香环，R1和R2相同或不同且独立地代表具有10到25个碳原子中的任意一种的烷基基团或具有10到25个碳原子中的任意一种的烯基基团，X和Y相同或不同且独立地代表—O—、—S—、—COO—、—OCO—、—CONH—或—NHCO—，m为0或1，n为0或1到6之间的自然数。
• COATING COMPOSITION AND MEDICAL DEVICE
  申请人：Terumo Kabushiki Kaisha

  公开号：EP2954908B1

  公开（公告）日：2018-08-08
• US6228391B1
  申请人：——

  公开号：US6228391B1

  公开（公告）日：2001-05-08
• US9981070B2
  申请人：——

  公开号：US9981070B2

  公开（公告）日：2018-05-29
• Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes
  作者：Zhi-xiang Yuan、Lu Jia、Lee Yong Lim、Ju-chun Lin、Gang Shu、Ling Zhao、Gang Ye、Xiao-xia Liang、Hongming Ji、Hua-lin Fu

  DOI：10.2147/ijn.s141095

  日期：——

  Previously, 3,5-dipentadecyloxybenzamidine hydrochloride (TRX-20)-modified liposomes were reported to specifically target mesangial cells (MCs) in glomeruli. To further gain a better understanding of the characteristics and potential application for glomerular diseases of TRX-20-modified liposomes, we synthesized TRX-20 and prepared TRX-20-modified liposomes (TRX-LPs) with different molar ratios - 6% (6%-TRX-LP), 11% (11%-TRX-LP), and 14% (14%-TRX-LP)-of TRX-20 to total lipid in the present study. All TRX-LPs exhibited concentration-dependent toxicity against the MCs at a lipid concentration ranging from 0.01 to 1.0 mg/mL with IC50 values of 3.45, 1.13, and 0.55 mg/mL, respectively. Comparison of the cell viability of TRX-LPs indicated that high levels of TRX-20 caused severe cell mortality, with 11%-TRX-LP showing the higher cytoplasmic accumulation in the MCs. Triptolide (TP) as a model drug was first loaded into 11%-TRX-LP and the liposomes were further modified with PEG5000 (PEG-TRX-TP-LP) in an attempt to prolong their circulation in blood and enhance TP-mediated immune suppression. Due to specific binding to MCs, PEG-TRX-TP-LP undoubtedly showed better anti-inflammatory action in vitro, evidenced by the inhibition of release of nitric oxide (NO) and tumor necrosis factor-a from lipopolysaccharide-stimulated MCs, compared with free TP at the same dose. In vivo, the PEG-TRX-TP-LP effectively attenuated the symptoms of membranous nephropathic (MN) rats and improved biochemical markers including proteinuria, serum cholesterol, and albumin. Therefore, it can be concluded that the TRX-modified liposome is an effective platform to target the delivery of TP to glomeruli for the treatment of MN.